Mesenchymal stem cell therapy (HepaStem) - Promethera Biosciences

Drug Profile

Mesenchymal stem cell therapy (HepaStem) - Promethera Biosciences

Alternative Names: hALDMSC - Promethera; HepaStem; Heterologous Human Adult Liver derived Progenitor Cells; HHALPC; human Adult Liver-Derived Mesenchymal Progenitor/Stem Cells - Promethera

Latest Information Update: 01 Feb 2017

Price : $50

At a glance

  • Originator Catholic University of Louvain
  • Developer Promethera Biosciences
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver disorders; Inborn urea cycle disorders
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Inborn urea cycle disorders; Liver failure
  • Phase I/II Liver disorders
  • Preclinical Non-alcoholic steatohepatitis
  • Research Haemophilia; Hepatic fibrosis
  • No development reported Glycogen storage disease type I; Phenylketonuria

Most Recent Events

  • 09 Jan 2017 Promethera Biosciences and LifeLiver enter into a strategic alliance to jointly develop HepaStem in South Korea
  • 14 Nov 2016 Pharmacodynamics data from a preclinical studies in Non-alcoholic steatohepatitis released by Promethera Biosciences
  • 11 Nov 2016 Early research in Haemophilia in Belgium before November 2016 (Promethera Biosciences pipeline, November 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top